Alto Neuroscience (NYSE:ANRO) Now Covered by Analysts at HC Wainwright

HC Wainwright assumed coverage on shares of Alto Neuroscience (NYSE:ANRO) in a research note published on Monday,Benzinga reports. The firm issued a buy rating and a $10.00 price target on the stock.

Separately, William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a research note on Friday, March 21st. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.40.

Alto Neuroscience Trading Up 24.8 %

Alto Neuroscience stock opened at $2.25 on Monday. Alto Neuroscience has a 52-week low of $1.60 and a 52-week high of $17.55. The company has a market cap of $60.80 million, a P/E ratio of -0.88 and a beta of 2.16. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. The business has a 50-day simple moving average of $3.13 and a two-hundred day simple moving average of $5.18.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Thursday, March 20th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.09. Analysts predict that Alto Neuroscience will post -2.54 EPS for the current year.

Hedge Funds Weigh In On Alto Neuroscience

Several hedge funds have recently modified their holdings of ANRO. Charles Schwab Investment Management Inc. increased its holdings in Alto Neuroscience by 182.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 186,968 shares of the company’s stock valued at $2,139,000 after acquiring an additional 120,779 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Alto Neuroscience by 84.5% in the third quarter. The Manufacturers Life Insurance Company now owns 65,805 shares of the company’s stock worth $753,000 after purchasing an additional 30,135 shares during the last quarter. FMR LLC lifted its position in shares of Alto Neuroscience by 1.4% in the third quarter. FMR LLC now owns 2,363,056 shares of the company’s stock worth $27,033,000 after buying an additional 32,040 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Alto Neuroscience by 619.2% during the third quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock valued at $49,000 after buying an additional 3,715 shares during the last quarter. Finally, MetLife Investment Management LLC bought a new position in Alto Neuroscience during the third quarter valued at approximately $146,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.